Former Chief Oncology Officer and Executive Vice President, Chris Boshoff, MD, PhD, will assume the role and lead all R&D functions including oncology.

Discover leading sales enablement and marketing intelligence solutions tailored for the pharmaceutical industry. Download our guide to market forecasts and industry insights.

The UK Minister of State for Science praised the UK’s thriving startup scene at the annual Jefferies London Healthcare Conference held in November.

Negative results from a Huntington’s trial add to a difficult year for Sage, which last month decided to overhaul its research, reconfigure its executive team and lay off a third of its staff.

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

Built around research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark, Valora Therapeutics is designing drugs to target glyco-immune checkpoints.

The first mpox vaccine authorised for children will be shipped to DRC in a 3.05 million-dose donation by the Japanese Government.

Tris Pharma has received additional ex-US approvals for its ADHD treatments, Quillivant XR and QuilliChew ER.

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Analysts see Trump’s victory raising the high-profile legislation’s chances of becoming law. But the realities of a lame duck Congress may cause its timeline for passage to slip back.

Diagnosed prevalent cases of Parkinson’s disease will grow at 1.94% annually in the seven major markets between 2023 and 2033.

Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab for malignant ascites.

Pfizer will work with Ampersand Biomedicines and Montai Therapeutics to find drugs for obesity and lung cancer, respectively, adding to collaborations it previously formed with other Flagship startups.

UK Health Secretary Wes Streeting outlaid the key shifts needed to fix a “fragmented” NHS at the Jefferies London Healthcare Conference.

The UK’s NICE has rejected a deal for the reimbursement of Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu for the third time.

The Phase III BROOKLYN trial saw HeFH patients randomly assigned in a 2:1 ratio to receive either obicetrapib or a placebo for 52 weeks.

Ron Lanton, Partner, Lanton Law, ways that the recent FDA PD-1 inhibitor label restrictions could influence future drug development strategies.

The latest news for pharma industry insiders.

Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous form of its cancer drug.

The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless founded a new startup and Novartis licensed another radiopharma drug.